Position in SYRE
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$2,405,836
-$126,184 QoQ
Shares Held
47,697
-38.3% QoQ
Ownership
0.055%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026DIMENSIONAL FUND ADVISORS LP holds $5,003,907,830 across 224 Biotechnology names. SYRE ranks #118 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
989,342 | $441,780,774 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
513,060 | $396,410,676 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
1,895,215 | $358,290,394 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
3,802,930 | $214,827,514 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
7,475,866 | $207,081,486 | |
| 6 | INCY |
Incyte Corp
|
1,975,544 | $185,938,199 | |
| 7 | EXEL |
Exelixis, Inc.
|
4,299,597 | $184,409,714 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
2,079,827 | $134,419,216 |
All Filings in SYRE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,405,836 | 47,697 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $2,532,020 | 77,290 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $1,411,460 | 84,216 | Shares | Sole | 2025-11-12 | |
| No filing history on record for this holder in this stock. | ||||||